Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T96144
|
||||
Former ID |
TTDS00080
|
||||
Target Name |
DNA topoisomerase II
|
||||
Synonyms |
DNA gyrase; Topo II; Topoisomerase II; Type II topoisomerase enzyme
|
||||
Target Type |
Successful
|
||||
Disease | Acute otitis media; Otitis externa [ICD9: 017.40, 055.2, 380, 381.0, 381.1, 381.2, 381.3, 381.4, 382; ICD10: H60, H65-H67] | ||||
Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10: C91.0] | |||||
Acute myeloid leukemia [ICD9: 205; ICD10: C92.0] | |||||
Breast cancer; Prostate cancer [ICD9: 174, 175, 185; ICD10: C50, C61] | |||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99] | |||||
Bladder cancer [ICD9: 188; ICD10: C67] | |||||
Condyloma [ICD10: A51.3] | |||||
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Diffuse large B-cell lymphoma; Follicular lymphoma; Multiple scierosis [ICD9:200.0, 202.0, 202.8, 340; ICD10: C81-C86, C82, C83.3, C85.1, G35] | |||||
External genital and perianal warts [ICD10: A63.0] | |||||
Endocarditis [ICD9: 421; ICD10: I33] | |||||
Fungal urinary tract infection [ICD10: N39.0] | |||||
Gastric cancer [ICD9: 151; ICD10: C16] | |||||
Gonococcal urethritis [ICD9: 98; ICD10: A54] | |||||
Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86] | |||||
Lung cancer [ICD9: 162; ICD10: C33-C34] | |||||
Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10: C00-C75, C7A, C7B, D10-D36, D3A] | |||||
Leukemia [ICD9: 208.9; ICD10: C90-C95] | |||||
Lung metastatic tumors [ICD9: 162; ICD10: C33, C34] | |||||
Liver cancer [ICD9: 140-229, 155, 203.0; ICD10: C22] | |||||
Mild alzheimer disease [ICD9: 331; ICD10: G30] | |||||
Ovarian cancer [ICD9: 183; ICD10: C56] | |||||
Pancreatic cancer [ICD9: 140-199, 140-229, 157, 210-229; ICD10: C25] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Tuberculosis [ICD9: 010-018; ICD10: A15-A19] | |||||
Urinary tract infections [ICD9: 599; ICD10: N39.0] | |||||
Unspecified [ICD code not available] | |||||
BioChemical Class |
ATP-hydrolyzing DNA topoisomerase
|
||||
Target Validation |
T96144
|
||||
EC Number |
EC 5.99.1.3
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Aclarubicin | Drug Info | Approved | Acute myeloid leukemia | [536361], [551871] |
Amsacrine | Drug Info | Approved | Acute lymphoblastic leukemia | [537102] | |
Cinoxacin | Drug Info | Approved | Urinary tract infections | [538497], [551871] | |
Ciprofloxacin+dexamethasone | Drug Info | Approved | Acute otitis media; Otitis externa | [536222] | |
Daunorubicin | Drug Info | Approved | Acute myeloid leukemia | [536361], [542069] | |
Dexrazoxane | Drug Info | Approved | Breast cancer | [538309], [542354] | |
Dhaq diacetate | Drug Info | Approved | Cancer | [537035] | |
Doxorubicin | Drug Info | Approved | Cancer | [536361], [542075] | |
Enoxacin | Drug Info | Approved | Urinary tract infections | [538528], [551871] | |
Epirubicin | Drug Info | Approved | Cancer | [535668] | |
Etoposide | Drug Info | Approved | Cancer | [536361], [541897] | |
Fleroxacin | Drug Info | Approved | Bacterial infections | [550115] | |
Fluoroquinolone | Drug Info | Approved | Bacterial infections | [536854] | |
Idarubicin | Drug Info | Approved | Acute myeloid leukemia | [535668], [542089] | |
Lomefloxacin | Drug Info | Approved | Bacterial infections | [538536] | |
Lucanthone | Drug Info | Approved | Cancer | [550759] | |
Mitoxantrone | Drug Info | Approved | Cancer | [536803], [542259] | |
Nalidixic Acid | Drug Info | Approved | Fungal urinary tract infection | [538242], [551871] | |
Novobiocin | Drug Info | Approved | Bacterial infections | [536773] | |
Pefloxacin | Drug Info | Approved | Gonococcal urethritis | [550741] | |
Podofilox | Drug Info | Approved | External genital and perianal warts | [551871] | |
Podophyllotoxin | Drug Info | Approved | Condyloma | [551871] | |
Quinolones | Drug Info | Approved | Tuberculosis | [536068] | |
Rosoxacin | Drug Info | Approved | Bacterial infections | [550779] | |
Teniposide | Drug Info | Approved | Acute lymphoblastic leukemia | [536361], [541923] | |
Valrubicin | Drug Info | Approved | Bladder cancer | [536361] | |
Fluoroquinolones | Drug Info | Phase 4 | Discovery agent | [525081] | |
Pixantrone | Drug Info | Phase 3 | Diffuse large B-cell lymphoma; Follicular lymphoma; Multiple scierosis | [521605], [542546] | |
Tirapazamine | Drug Info | Phase 3 | Mild alzheimer disease | [521770] | |
MTC-DOX | Drug Info | Phase 2/3 | Liver cancer | [521507] | |
13-DEOXYADRIAMYCIN HYDROCHLORIDE | Drug Info | Phase 2 | Solid tumours | [521653] | |
Berubicin | Drug Info | Phase 2 | Cancer | [522133] | |
CAP-7.1 | Drug Info | Phase 2 | Cancer | [524688] | |
Doxorubicin-eluting beads | Drug Info | Phase 2 | Liver cancer | [548497] | |
Elsamitrucin | Drug Info | Phase 2 | Late-stage solid tumors | [527240] | |
GPX-150D | Drug Info | Phase 2 | Breast cancer | [524956] | |
GSK2140944 | Drug Info | Phase 2 | Bacterial infections | [524614] | |
INNO-206 | Drug Info | Phase 2 | Solid tumours | [523878] | |
Liposomal encapsulated doxorubicin (LED) | Drug Info | Phase 2 | Breast cancer; Prostate cancer | [531792] | |
PYRAZOLOACRIDINE | Drug Info | Phase 2 | Colorectal cancer | [521455] | |
Sabarubicin | Drug Info | Phase 2 | Solid tumours | [521498] | |
Salvicine | Drug Info | Phase 2 | Cancer | [528379] | |
SNS-595 | Drug Info | Phase 2 | Ovarian cancer | [536839] | |
Valrubicin | Drug Info | Phase 2 | Psoriasis | [551871] | |
XR-5000 | Drug Info | Phase 2 | Colorectal cancer | [526364] | |
F-14512 | Drug Info | Phase 1/2 | Cancer | [548580] | |
L-377202 | Drug Info | Phase 1/2 | Solid tumours | [522803] | |
BMY-43748 | Drug Info | Phase 1 | Bacterial infections | [531122] | |
Daniquidone | Drug Info | Phase 1 | Lymphoma | [521991] | |
Iboctadekin + Doxil | Drug Info | Phase 1 | Ovarian cancer | [522292], [550972] | |
MLN-576 | Drug Info | Phase 1 | Acute lymphoblastic leukemia | [526301] | |
NK-314 | Drug Info | Phase 1 | Solid tumours | [547889] | |
Tafluposide | Drug Info | Phase 1 | Cancer | [547025] | |
TAS-103 | Drug Info | Phase 1 | Solid tumours | [546363] | |
XR-5944 | Drug Info | Phase 1 | Gastric cancer | [526044] | |
Nemorubicin | Drug Info | Preclinical | Solid tumours | [547011] | |
Amifloxacin | Drug Info | Discontinued in Phase 2 | Discovery agent | [544658] | |
BW-773U82 | Drug Info | Discontinued in Phase 2 | Solid tumours | [545287] | |
ELINAFIDE MESILATE | Drug Info | Discontinued in Phase 2 | Solid tumours | [545863] | |
GL-331 | Drug Info | Discontinued in Phase 2 | Colorectal cancer | [545233] | |
KW-2170 | Drug Info | Discontinued in Phase 2 | Breast cancer | [545689] | |
LOSOXANTRONE | Drug Info | Discontinued in Phase 2 | Breast cancer | [544730] | |
Merbarone | Drug Info | Discontinued in Phase 2 | Pancreatic cancer | [544761] | |
Mitonafide | Drug Info | Discontinued in Phase 2 | Solid tumours | [545276] | |
NC-190 | Drug Info | Discontinued in Phase 2 | Solid tumours | [544763] | |
SUPER-LEU-DOX | Drug Info | Discontinued in Phase 2 | Cancer | [546627] | |
Banoxantrone | Drug Info | Discontinued in Phase 1 | Acute lymphoblastic leukemia | [545759] | |
Teloxantrone | Drug Info | Discontinued in Phase 1 | Cancer | [544724] | |
TOP-53 | Drug Info | Discontinued in Phase 1 | Lung metastatic tumors | [545776] | |
A-62176 | Drug Info | Terminated | Discovery agent | [546382] | |
A-74932 | Drug Info | Terminated | Lung cancer | [545604] | |
BE-22179 | Drug Info | Terminated | Leukemia | [545707] | |
Datelliptium chloride | Drug Info | Terminated | Breast cancer | [544836] | |
Doxorubicin-CEA conjugate | Drug Info | Terminated | Breast cancer | [546274] | |
ER-37328 | Drug Info | Terminated | Discovery agent | [546422] | |
Garenoxacin | Drug Info | Terminated | Endocarditis | [536094] | |
Inhibitor | 1,3,7-trihydroxyacridone | Drug Info | [534989] | ||
1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one | Drug Info | [531025] | |||
2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one | Drug Info | [530919] | |||
2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one | Drug Info | [530919] | |||
3,3'-(4-phenylpyridine-2,6-diyl)diphenol | Drug Info | [530854] | |||
3-(2,6-diphenylpyridin-4-yl)phenol | Drug Info | [530854] | |||
3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol | Drug Info | [530854] | |||
3-(2-phenyl-6-(thiophen-3-yl)pyridin-4-yl)-phenol | Drug Info | [530854] | |||
3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol | Drug Info | [530854] | |||
3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol | Drug Info | [530854] | |||
3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol | Drug Info | [530854] | |||
4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin | Drug Info | [551351] | |||
4'-Demethyl-epipodophyllotoxin | Drug Info | [551351] | |||
4,4'-(4-phenylpyridine-2,6-diyl)diphenol | Drug Info | [530854] | |||
4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine | Drug Info | [530553] | |||
7-chloro-1,3-dihydroxyacridone | Drug Info | [534989] | |||
A-62176 | Drug Info | [534726] | |||
Aclarubicin | Drug Info | [534989], [535576] | |||
Amifloxacin | Drug Info | [537698] | |||
Amsacrine | Drug Info | [535303] | |||
Cinoxacin | Drug Info | [534884] | |||
Clorobiocin | Drug Info | [551404] | |||
DEMETHYLZEYLASTERONE | Drug Info | [526181] | |||
Dhaq diacetate | Drug Info | [535026], [537035] | |||
ELINAFIDE MESILATE | Drug Info | [525631], [551871] | |||
Ellipticine | Drug Info | [535054] | |||
Enoxacin | Drug Info | [537741] | |||
ER-37328 | Drug Info | [535624] | |||
Fleroxacin | Drug Info | [537995] | |||
Fluoroquinolone | Drug Info | [536854] | |||
Fluoroquinolones | Drug Info | [535054] | |||
Garenoxacin | Drug Info | [535226] | |||
GSK2140944 | Drug Info | [532750] | |||
Howiinol A (GHM-10) | Drug Info | [535138] | |||
Iboctadekin + Doxil | Drug Info | [550963] | |||
ICRF-154 | Drug Info | [535604] | |||
ICRF-193 | Drug Info | [535604] | |||
Lomefloxacin | Drug Info | [535555] | |||
Lucanthone | Drug Info | [536070] | |||
LUPEOL | Drug Info | [526233] | |||
Makaluvamine N | Drug Info | [534377] | |||
Nalidixic Acid | Drug Info | [537698] | |||
Novobiocin | Drug Info | [536981] | |||
Olean-12-en-3beta,15alpha-diol | Drug Info | [526233] | |||
Oxolinic acid | Drug Info | [537698] | |||
Pefloxacin | Drug Info | [537741] | |||
Phosphoaminophosphonic Acid-Adenylate Ester | Drug Info | [551374] | |||
Podophyllotoxin | Drug Info | [535080] | |||
Pumiliotoxin 251D | Drug Info | [536773] | |||
Quinolones | Drug Info | [536068] | |||
Rosoxacin | Drug Info | [537724] | |||
TOPOSTATIN | Drug Info | [526096] | |||
Valrubicin | Drug Info | [537728] | |||
Modulator | 13-DEOXYADRIAMYCIN HYDROCHLORIDE | Drug Info | [1572591] | ||
A-74932 | Drug Info | ||||
Banoxantrone | Drug Info | [1572591] | |||
BE-22179 | Drug Info | [533914] | |||
Berubicin | Drug Info | [1572591] | |||
BMY-43748 | Drug Info | [531122], [551871] | |||
BW-773U82 | Drug Info | [534741] | |||
CAP-7.1 | Drug Info | [1572591] | |||
Daniquidone | Drug Info | ||||
Datelliptium chloride | Drug Info | [531121] | |||
Daunorubicin | Drug Info | [556264] | |||
Dexrazoxane | Drug Info | [556264] | |||
Doxorubicin | Drug Info | [556264] | |||
Doxorubicin-CEA conjugate | Drug Info | [556264] | |||
Doxorubicin-eluting beads | Drug Info | [1572591] | |||
doxorubicin-LL2 conjugate, Immunomedics | Drug Info | [1572605] | |||
doxorubicin-peptide-PEG conjugate, Watson | Drug Info | [1572605] | |||
Elsamitrucin | Drug Info | [527240] | |||
Epirubicin | Drug Info | [556264] | |||
Etoposide | Drug Info | ||||
F-14512 | Drug Info | ||||
GL-331 | Drug Info | [528299] | |||
GPX-150D | Drug Info | ||||
Idarubicin | Drug Info | [556264] | |||
INNO-206 | Drug Info | [1572591] | |||
KW-2170 | Drug Info | [526638] | |||
L-377202 | Drug Info | [1572591] | |||
Liposomal encapsulated doxorubicin (LED) | Drug Info | [1572591] | |||
LOSOXANTRONE | Drug Info | ||||
Merbarone | Drug Info | [532018] | |||
Mitonafide | Drug Info | [534235] | |||
Mitoxantrone | Drug Info | [534547] | |||
MLN-576 | Drug Info | [526301] | |||
MTC-DOX | Drug Info | [1572591] | |||
NC-190 | Drug Info | [526888] | |||
Nemorubicin | Drug Info | [532120] | |||
NK-314 | Drug Info | [536762] | |||
Pixantrone | Drug Info | [1572591] | |||
Podofilox | Drug Info | ||||
PYRAZOLOACRIDINE | Drug Info | [534593] | |||
Sabarubicin | Drug Info | [1572591] | |||
Salvicine | Drug Info | [528379], [536485] | |||
SNS-595 | Drug Info | ||||
SUPER-LEU-DOX | Drug Info | [1572591] | |||
Tafluposide | Drug Info | [526671] | |||
TAS-103 | Drug Info | ||||
Teloxantrone | Drug Info | ||||
Teniposide | Drug Info | [556264] | |||
Tirapazamine | Drug Info | [1572591] | |||
TOP-53 | Drug Info | [535107] | |||
XR-5000 | Drug Info | [526364] | |||
XR-5944 | Drug Info | [526044] | |||
Binder | Ciprofloxacin+dexamethasone | Drug Info | [536222] | ||
Toll-like receptor 4 inhibition | Drug Info | [536773] | |||
References | |||||
Ref 521455 | ClinicalTrials.gov (NCT00003802) Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma. U.S. National Institutes of Health. | ||||
Ref 521498 | ClinicalTrials.gov (NCT00027781) MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy. U.S. National Institutes of Health. | ||||
Ref 521507 | ClinicalTrials.gov (NCT00034333) Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer. U.S. National Institutes of Health. | ||||
Ref 521605 | ClinicalTrials.gov (NCT00088530) BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health. | ||||
Ref 521653 | ClinicalTrials.gov (NCT00123877) Study of GPX-100 in the Treatment of Metastatic Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 521770 | ClinicalTrials.gov (NCT00262821) Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer. U.S. National Institutes of Health. | ||||
Ref 521991 | ClinicalTrials.gov (NCT00450502) Safety of Batracylin in Patients With Solid Tumors and Lymphomas. U.S. National Institutes of Health. | ||||
Ref 522133 | ClinicalTrials.gov (NCT00538343) RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases. U.S. National Institutes of Health. | ||||
Ref 522292 | ClinicalTrials.gov (NCT00659178) Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer. U.S. National Institutes of Health. | ||||
Ref 522803 | ClinicalTrials.gov (NCT00987753) Study Evaluating the Safety and Tolerability of L-377202. U.S. National Institutes of Health. | ||||
Ref 523878 | ClinicalTrials.gov (NCT01580397) Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer. U.S. National Institutes of Health. | ||||
Ref 524614 | ClinicalTrials.gov (NCT02045797) Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections. U.S. National Institutes of Health. | ||||
Ref 524688 | ClinicalTrials.gov (NCT02094560) CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors. U.S. National Institutes of Health. | ||||
Ref 524956 | ClinicalTrials.gov (NCT02267083) Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma. U.S. National Institutes of Health. | ||||
Ref 525081 | ClinicalTrials.gov (NCT02357407) Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model. U.S. National Institutes of Health. | ||||
Ref 526044 | Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67. | ||||
Ref 526301 | In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28. | ||||
Ref 526364 | Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80. | ||||
Ref 527240 | Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72. | ||||
Ref 528379 | Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006 Nov;70(5):1593-601. Epub 2006 Aug 16. | ||||
Ref 531122 | Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503. | ||||
Ref 531792 | Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10. | ||||
Ref 535668 | New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31. | ||||
Ref 536068 | The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64. | ||||
Ref 536094 | Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. | ||||
Ref 536222 | Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 536773 | How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. | ||||
Ref 536803 | Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. J Neurol Sci. 2008 Oct 15;273(1-2):144-7. Epub 2008 Aug 6. | ||||
Ref 536854 | Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6. | ||||
Ref 537035 | The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7. Epub 2009 Jan 27. | ||||
Ref 537102 | Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) utricle. J Assoc Res Otolaryngol. 2009 Jun;10(2):191-203. Epub 2009 Feb 25. | ||||
Ref 538242 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071919. | ||||
Ref 538309 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076068. | ||||
Ref 538497 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018067. | ||||
Ref 538528 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616. | ||||
Ref 538536 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020013. | ||||
Ref 541897 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815). | ||||
Ref 541923 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6843). | ||||
Ref 542069 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063). | ||||
Ref 542075 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069). | ||||
Ref 542089 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083). | ||||
Ref 542259 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242). | ||||
Ref 542354 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7330). | ||||
Ref 542546 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7544). | ||||
Ref 544658 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000457) | ||||
Ref 544724 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000732) | ||||
Ref 544730 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000754) | ||||
Ref 544761 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000894) | ||||
Ref 544763 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000904) | ||||
Ref 544836 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001278) | ||||
Ref 545233 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002538) | ||||
Ref 545276 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002671) | ||||
Ref 545287 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002707) | ||||
Ref 545604 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003878) | ||||
Ref 545689 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004178) | ||||
Ref 545707 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004286) | ||||
Ref 545759 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004590) | ||||
Ref 545776 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004663) | ||||
Ref 545863 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005099) | ||||
Ref 546274 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194) | ||||
Ref 546363 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007714) | ||||
Ref 546382 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007798) | ||||
Ref 546422 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008013) | ||||
Ref 546627 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009260) | ||||
Ref 547011 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012041) | ||||
Ref 547025 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012192) | ||||
Ref 547889 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020174) | ||||
Ref 548497 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026037) | ||||
Ref 525631 | Solution structure and dynamics of a complex between DNA and the antitumor bisnaphthalimide LU-79553: intercalated ring flipping on the millisecond time scale. Biochemistry. 1999 Nov 16;38(46):15104-15. | ||||
Ref 526044 | Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67. | ||||
Ref 526096 | J Nat Prod. 2001 Feb;64(2):204-7.Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. | ||||
Ref 526181 | J Nat Prod. 2001 Oct;64(10):1294-6.Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica. | ||||
Ref 526233 | J Nat Prod. 2001 Dec;64(12):1545-7.Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity. | ||||
Ref 526301 | In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28. | ||||
Ref 526364 | Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80. | ||||
Ref 526671 | Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73. | ||||
Ref 526888 | The topoisomerase II-inhibitor NC-190 reduces the level of thymidine kinase mRNA in murine tumor cells. Res Commun Mol Pathol Pharmacol. 2002;111(1-4):77-87. | ||||
Ref 527240 | Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72. | ||||
Ref 528299 | GL331, a topoisomerase II inhibitor, induces radiosensitization of human glioma cells. Anticancer Res. 2006 May-Jun;26(3A):2149-56. | ||||
Ref 528379 | Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006 Nov;70(5):1593-601. Epub 2006 Aug 16. | ||||
Ref 530553 | Bioorg Med Chem Lett. 2010 Jan 1;20(1):42-7. Epub 2009 Nov 14.2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. | ||||
Ref 530854 | Bioorg Med Chem. 2010 May 1;18(9):3066-77. Epub 2010 Mar 27.Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines. | ||||
Ref 530919 | Bioorg Med Chem. 2010 Jun 1;18(11):3974-84. Epub 2010 Apr 18.Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents. | ||||
Ref 531025 | Eur J Med Chem. 2010 Sep;45(9):4221-8. Epub 2010 Jun 17.Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues. | ||||
Ref 531121 | Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302. | ||||
Ref 531122 | Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503. | ||||
Ref 532018 | The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res. 2012 Oct-Nov;738-739:45-51. | ||||
Ref 532120 | The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs. Bioorg Med Chem. 2012 Dec 15;20(24):6979-88. | ||||
Ref 532750 | Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014 Jul;52(7):2629-32. | ||||
Ref 533914 | A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity. J Antibiot (Tokyo). 1994 Feb;47(2):129-35. | ||||
Ref 534235 | Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother. 1996 Mar;40(3):706-9. | ||||
Ref 534377 | J Nat Prod. 1997 Apr;60(4):408-10.Makaluvamine N: a new pyrroloiminoquinone from Zyzzya fuliginosa. | ||||
Ref 534547 | Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. | ||||
Ref 534593 | Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4(3):683-91. | ||||
Ref 534726 | J Med Chem. 1998 Oct 22;41(22):4273-8.Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. | ||||
Ref 534741 | Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35. | ||||
Ref 534884 | The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. | ||||
Ref 534989 | 1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34. | ||||
Ref 535026 | Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem. 2000 Aug 18;275(33):25231-8. | ||||
Ref 535054 | In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors. Southeast Asian J Trop Med Public Health. 2000 Mar;31(1):118-22. | ||||
Ref 535080 | Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39. | ||||
Ref 535107 | DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry. 2001 Jan 23;40(3):712-8. | ||||
Ref 535138 | Anticancer effect of Howiinol A and its mechanism of action. J Asian Nat Prod Res. 1999;2(1):1-19. | ||||
Ref 535226 | The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J Antimicrob Chemother. 2001 Aug;48(2):195-201. | ||||
Ref 535303 | Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21. | ||||
Ref 535555 | Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22. | ||||
Ref 535576 | Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15. | ||||
Ref 535604 | The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82. | ||||
Ref 535624 | Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. Mol Cancer Ther. 2002 Jan;1(3):169-75. | ||||
Ref 536068 | The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64. | ||||
Ref 536070 | Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Cell Stress Chaperones. 2005 Spring;10(1):37-45. | ||||
Ref 536222 | Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. | ||||
Ref 536485 | Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5. | ||||
Ref 536762 | NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20. Epub 2008 Jul 2. | ||||
Ref 536773 | How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. | ||||
Ref 536854 | Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6. | ||||
Ref 536981 | Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9. | ||||
Ref 537035 | The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7. Epub 2009 Jan 27. | ||||
Ref 537698 | Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. | ||||
Ref 537724 | Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601. | ||||
Ref 537728 | Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5. | ||||
Ref 537741 | Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. | ||||
Ref 551351 | Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod. 1989 May-Jun;52(3):606-13. | ||||
Ref 551404 | The high-resolution crystal structure of a 24-kDa gyrase B fragment from E.coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins. 1997 May;28(1):41-52. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.